Overview

A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

Status:
Terminated
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and activity of the study drug known as LY3023414 in combination with necitumumab in participants with metastatic squamous non-small cell lung cancer (NSCLC).
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
SCRI Development Innovations, LLC
Treatments:
Antibodies, Monoclonal
Necitumumab